Understanding the risks associated with the use of new psychoactive substances (NPS): High variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products
Graphical abstract
The risk derived from the intra- and inter-product concentration variability, which may expose users to unexpected dosages, the risk derived from the lack of quality in the manufacture process and mislabelled preparations, which doesn't provide users the basic information about what they consume, and the risk derived from the simultaneous consumption of different psychoactive substances, whose pharmacodynamics and adverse effects are almost unknown, are a source of concern for possible serious health related consequences.
Section snippets
Background
New psychoactive substances (NPS), are now a large group of substances of abuse not yet completely controlled by international drug conventions, which may pose a public health threat UNODC, 2013a. Many of these substances were synthesized and patented in the early 1970s or even earlier, but only recently their chemistry have been modified to produce new substances with similar subjective effects to established recreational drugs UNODC, 2013a. ‘Legal highs’, ‘herbal highs’, ‘research chemicals’
Case #1 – how much of it?
The first event, from which Case #1 started, was a medical report about a young boy (age 18) who presented a critical clinical status caused by the consumption of an unknown white powder. When the boy was admitted to the hospital he presented hallucinations, agitation, confusion, memory loss and clonus and amphetamine overdose was initially suspected. At screening tests performed at the emergency department he was also found positive to cannabinoids and was hospitalized under sedation. After a
Case #2 – what is it… actually?
Case #2 concerns a seizure consisting of 16 coloured, industrial made packages, each containing 3 white capsules filled with about 500 mg each of yellowish fine powder, which was submitted to the LIATF for analysis. All the packages were bar-coded and reported clearly, printed or attached on the rear, lists of the ingredients contained in the capsules. According to the package labelling, the capsules were of two kinds: type-A, containing amino acid blend, gelatine (capsule shell),
Case #3 – how many are they?
The third case report regards the risk related to poly-substance consumption. In this Case, 50 industrial made packages containing about 2 g each of herbal materials being sold in a so-called ‘smart-shop’ were seized under suspicion of containing illicit active ingredients and submitted to the LIATF for analysis. According to the packaging, these were divided into three groups: A (30 packages), B (18 packages) and C (2 packages). Along with these, another bigger wrapping with no label or
Discussion
The risk derived from the intra- and inter-product concentration variability which may expose users to unexpected dosages has been represented in Case #1. Although herbal materials containing NPS are prepared to evoke traditional cannabis, it should be noted that synthetic cannabinoids appear to be more potent and to have more pronounced and severe cardiovascular adverse effects than traditional cannabis Lapoint et al., 2011, Tomiyama and Funada., 2014, Fantegrossi et al., 2014, Young et al.,
Conclusions
The aim of this paper was to stress the importance of possible risks of toxicological effects after the consumption of NPS-containing home made and industrial products. In particular, (1) the risk derived from the intra- and inter-product concentration variability (Case #1), which may expose users to unexpected dosages, (2) the risk derived from the lack of quality in the manufacture process (Case #2), which doesn’t provide users the basic information about what they consume, and (3) the risk
Conflict of interest
The authors declare no conflict of interest.
References (69)
- et al.
3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online
Toxicol. Lett.
(2012) - et al.
Synthetic cannabinoids: analysis and metabolites
Life Sci.
(2014) Synthetic cannabinoid JWH-018 and psychosis: an explorative study
Drug Alcohol Depend.
(2011)- et al.
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity?
Life Sci.
(2014) - et al.
Synthetic cannabinoid intoxication: a case series and review
J. Emerg. Med.
(2013) - et al.
Identification and characterization of the new designer drug 4′-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography-tandem mass spectrometry (LC–MS/MS) screening method for seven different methcathinone analogs
Forensic Sci. Int.
(2011) - et al.
The analytical investigation of synthetic street drugs containing cathinone analogs
Forensic Sci. Int.
(2014) - et al.
Spice: a never ending story?
Forensic Sci. Int.
(2009) - et al.
Psychostimulant-like effects of p-fluoroamphetamine in the rat
Eur. J. Pharmacol.
(1995) - et al.
Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors
Toxicol. Appl. Pharmacol.
(2013)
Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry
J. Chromatogr. A
Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death
Toxicol. Appl. Pharmacol.
Spice drugs as a new trend: mode of action, identification and legislation
Toxicol. Lett.
Drugs for youth via Internet and the example of mephedrone
Toxicol. Lett.
Determination of illicit drugs in seized materials: role of sampling and analysis in estimation of measurement uncertainty
Forensic Sci. Int.
JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist
Br. J. Pharmacol.
Analyses of second-generation ‘legal highs' in the UK: initial findings
Drug Test. Anal.
Differential drug–drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy
J. Pharmacol. Exp. Ther.
Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project
Hum. Psychopharmcol.
Drug-related deaths in the UK: January–December 2012
National Programme on Substance Abuse Deaths (NPSAD) International Centre for Drug Policy (ICDP), Annual Report
European Monitoring Centre for Drugs and Drug Addiction. Risk Assessment Report of a New Psychoactive Substance: 4-methylmethcathinone (Mephedrone)
Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds
J. Mass Spectrom.
Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology
Drug Test. Anal.
Understanding the ‘ Spice’ Phenomenon Luxembourg
New challenges and innovation in forensic toxicology: focus on the “new psychoactive substances”
J. Chromatogr. A
Ischemic stroke after use of the synthetic marijuana “Spice”
Neurology
Gas chromatography/mass spectrometry determination of mephedrone in drug seizures after derivatization with 2,2, 2-trichloroethyl chloroformate
Rapid Commun. Mass Spectrom.
Potenzialità della spettrometria di massa ad elevata risoluzione ed elevata accuratezza nella caratterizzazione strutturale delle nuove sostanze psicoattive ad azione amfetamino-simile
Ital. J. Addict.
Toxicity from the recreational use of 1-benzylpiperazine
Clin. Toxicol. (Phila.)
Cited by (44)
An overview of New Psychoactive Substances (NPS) in northeast Brazil: NMR-based identification and analysis of ecstasy tablets by GC-MS
2023, Forensic Science InternationalDeliberate evasion of narcotic legislation: Trends visualized in commercial mixtures of new psychoactive substances analyzed by GC-solid deposition-FTIR
2021, Forensic ChemistryCitation Excerpt :Therefore, minimal focus was set on chromatographic resolution. Although most NPS are sold in formulations with only one active ingredient, multi-drug mixtures are sometimes also encountered in seized samples or even deliberately produced, marketed and sold as legal highs. [8,67,68] Currently, such liquid mixtures are freely available at smartshops and from several websites in The Netherlands.
Screen-printed electrodes: Transitioning the laboratory in-to-the field
2021, Talanta OpenSecondhand marijuana smoke (SHMS): Exposure occurrence, biological analysis and potential health effects
2020, Advances in Molecular ToxicologyCaffeine-based food supplements and beverages: Trends of consumption for performance purposes and safety concerns
2018, Food Research InternationalCitation Excerpt :The caffeine concentration of the product or the “energy dose” results then from adding up all the contributor ingredients (Belza, Toubro, & Astrup, 2009; Campbell et al., 2013). In addition, some of these products may contain “proprietary blends” of multiple ingredients, and different stimulants of the CNS, that together may increase the risk of adverse events in some individuals, such as anxiety, seizures, cardiac and gastrointestinal symptoms or blood pressure increase (Eudy et al., 2013; Zamengo, Frison, Bettin, & Sciarrone, 2014). Furthermore, the promotion and marketing of such products include sometimes inadequate health claims and misleading nutrition labels (Eudy et al., 2013).